Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Hormone receptor positive HER2 negative breast cancer

Recruiting

Registered drugNo placebo

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Belgium

Participants:18–64 years
Substances:Anastrozole

Contact Research Centre

Breast cancer+1

Recruiting

Registered drug

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Registered drug

Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Follicle centre lymphoma follicular grade I, II - III

Recruiting

Registered drugNo placebo

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide

Contact Research Centre

Breast cancer+2

Recruiting

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capivasertib

Contact Research Centre

B-cell lymphoma+1

Recruiting

InvestigationalNo placebo

Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Valemetostat Tosilate

Contact Research Centre

Renal cell carcinoma

Recruiting

Registered drugNo placebo

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Axitinib

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Registered drugNo placebo

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Registered drugNo placebo

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hormone-dependent prostate cancer

Recruiting

Registered drugNo placebo

Study on the Effectiveness of Triptorelin, Goserelin Acetate, and Enzalutamide in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Degarelix

Contact Research Centre

Neuroendocrine tumour+2

Recruiting

Registered drugNo placebo

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Everolimus

Contact Research Centre

Breast cancer

Not yet recruiting

Registered drugNo placebo

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Find therapies in clinical trials near you

21 trials match your criteria

Hormone receptor positive HER2 negative breast cancer

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Breast cancer+1

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Acute myeloid leukaemia

Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Follicle centre lymphoma follicular grade I, II - III

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Breast cancer+2

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

B-cell lymphoma+1

Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma

Renal cell carcinoma

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Plasma cell myeloma refractory

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Hormone receptor positive HER2 negative breast cancer

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Hormone-dependent prostate cancer

Study on the Effectiveness of Triptorelin, Goserelin Acetate, and Enzalutamide in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer

Neuroendocrine tumour+2

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Breast cancer

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.